|
Dr. Jens Eckstein is a partner in TVM Capital’s Boston office. In addition to Magen Biosciences, he is actively involved in TVM Capital’s investments in Sirtris Pharmaceuticals, CoNCERT Pharmaceuticals and SelectX Pharmaceuticals. Prior to joining TVM Capital, he was Director, Lead Discovery and Research IT at Enanta Pharmaceuticals, Inc., where he directed the company's lead discovery and knowledge management programs for novel therapeutics in hepatitis, asthma, psoriasis and other autoimmune disorders. Prior to joining Enanta, he managed research groups in biochemistry, structural biology, and computational chemistry at Mitotix, Inc. (now GPC-Biotech). At Mitotix he led the $48 million research collaboration with the BASF Bioresearch Corporation (BBC) on Cdc25 anticancer therapeutics. Dr. Eckstein earned his doctorate, summa cum laude, in biological chemistry at the University of Konstanz and Harvard University. He was a postdoctoral fellow at the University of California in San Francisco (UCSF). | 